inosine-pranobex and Lymphoproliferative-Disorders

Topics: Adult; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies

The ability of methisoprinol to antagonize the serum-inhibiting activity present in the sera of patients affected by immunoproliferative diseases (Hodgkin's disease and multiple myeloma) was investigated. Using a chemotaxis test, it was found that whereas donor leukocytes preincubated in patient sera exhibited impaired chemotaxis, the presence of methisoprinol (500 micrograms/ml) during the preincubation caused a significant recovery of this leukocyte function. Since the results exclude the assumption of a non-specific stimulation of cell motility, two hypotheses appeared possible for the action of methisoprinol: either an antagonistic activity against the blocking factor at the receptor or the metabolic level, or a direct inactivation of this factor. The clinical implications, with regard to the prophylaxis of infections and a better response to chemotherapy, are discussed.

Topics: Adult; Aged; Antibodies; Binding, Competitive; Chemotaxis, Leukocyte; Female; Hodgkin Disease; Humans; In Vitro Techniques; Inosine; Inosine Pranobex; Leukocytes; Lymphoproliferative Disorders; Male; Middle Aged; Multiple Myeloma; Waldenstrom Macroglobulinemia